FDA Letter API

VapeCentric, Inc.

Letter data

Company
VapeCentric, Inc.
Recipient
Michael Daneshrad | VapeCentric, Inc. | 30101 Agoura Court | Suite 233 | Agoura Hills | , | CA | 91301 | United States | sales@vapecentric.com | mike@vapecentric.com
Issue date
2020-11-20
Posted date
Not available
FDA office
Office of Compliance and Enforcement
Subject
Not available
Product
Not available
CMS ID
607375
Reference number
RW2001268
FEI
Not available
Inspection dates
2020-05-18 to 2020-09-27

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER VapeCentric, Inc. MARCS-CMS 607375 — November 20, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: RW2001268 Recipient: Recipient Name Michael Daneshrad VapeCentric, Inc. 30101 Agoura Court Suite 233 Agoura Hills , CA 91301 United States sales@vapecentric.com mike@vapecentric.com Issuing Office: Office of Compliance and Enforcement United States Dear Michael Daneshrad: On April 27, 2020, the Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) issued a Warning Letter informing you that your e-liquid product (e.g. Pink Sticks) was adulterated under section 902(6)(A) of the Federal Food, Drug and Cosmetic Act (FD&C Act) and misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. In addition, a conference call was held between FDA and VapeCentric, Inc. (VapeCentric) on August 17, 2020. On May 18, 2020 and September 27, 2020, FDA received response letters from Phil Daman, Esq. at Daman & Associates, LLP on behalf of VapeCentric, representing that corrective actions were taken to address the violation identified in the Warning Letter and related concerns. Based upon our evaluation, it appears the stated corrections have been made. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure compliance with the FD&C Act and its implementing regulations or other relevant legal authority. This letter will not preclude regulatory action should violations be observed in the future. If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov . Sincerely, /S/ Ann Simoneau, J.D. Director Office of Compliance and Enforcement Center for Tobacco Products VIA UPS and Electronic Mail cc: Michael Daneshrad 5015 Blackpool Avenue Oak Park, CA 91377 Phil Daman, Esq. 369 Lexington Ave., 3rd Floor New York, NY 10017 phillip.daman@damanllp.com GoDaddy.com, LLC abuse@godaddy.com Google, LLC google-cloud-compliance@google.com Content current as of: 12/01/2020